Global Rise in Alopecia ⁢Areata ⁣Cases Examined

‍ ‌ updated June 02, 2025
‌ ⁣

the global incidence of alopecia areata, a common autoimmune disorder ‍causing hair loss, has increased⁤ substantially from 1990‍ to 2021,​ according to a study ⁢in the⁢ Journal‍ of Cosmetic Dermatology. While age-standardized incidence rates (ASIR) ⁢saw a slight decline, the overall number ‌of cases rose, underscoring the need⁤ for further investigation into socioeconomic factors⁢ and associated health burdens.

Alopecia areata affects⁤ roughly 2% of the​ worldS ⁣population, with⁤ women over 45‌ being the most commonly affected. The condition is frequently enough associated with an increased ​risk of mental health conditions, including anxiety and depression. Studies​ show that individuals with alopecia are 56% more likely to take time off work and face an‌ 82% higher risk of unemployment.

Researchers analyzed data from the Global Burden of Disease study 2021,encompassing 204 countries and territories. the data included‌ deaths, years of life lost, and disability-adjusted life years.

The study revealed that the global incidence of alopecia areata grew from 20.43 million​ in 1990 to 30.89 million in⁣ 2021.However, the ASIR dropped slightly ‍from 393.7 per‌ 100,000 individuals in 1990 to 379.5 per 100,000 individuals in 2021. This translates to an Estimated Annual Percentage Change (EAPC) of –0.14 and‌ an⁤ Average Annual Percentage Change ​(AAPC) of –0.12, indicating a slight global decline in the rate of new cases.

In 2021, north America, south⁣ America,‍ Southeast Asia, and Australia reported the highest ASIR values. Specifically, the ASIR in the ‌U.S. ​exceeded 550 per 100,000 individuals, while Canada’s ASIR⁤ surpassed 500 per 100,000 individuals.‌ Conversely, ​Africa‌ and the​ Middle East reported the‍ lowest ASIR⁢ values.

Between 1990 and 2021, Eastern Europe and Russia saw a decrease in alopecia areata cases, while ⁤North America, Argentina, China, and South Korea experienced increases of less than 50%. Most of ‍Africa experienced a greater ​than 100% ‍increase in incidence. Interestingly, countries with higher incidence rates ‌in 2021 showed a downward trend over the past 32 years, while countries with lower incidence rates had an upward trend.

Factors such as ⁣sex, ‌age, socioeconomic indices (SDI), Human Advancement Index (HDI), and geographic location influenced annual alopecia areata cases and ASIRs. Women had twice the ‌incidence and significantly higher ASIRs than men from 1990 to 2021. The Americas recorded⁤ the highest ASIR, followed by Europe, Asia, and Africa.

The ‍25 to 40⁣ age group experienced the highest ‌incidence ‍of alopecia areata, with the 30 to 34 age group having​ the highest ASIR. ASIR for ​those under‌ 20 or over 70 was significantly​ lower. Regions with higher SDI ⁢experienced significantly higher ASIR, but a lower EAPC in incidence.

The study also found a strong interrelationship between‍ alopecia areata and ‍comorbidities such ⁢as atopic dermatitis, dietary iron deficiency, viral ‌skin‌ diseases, and ⁢depressive disorders. Specific associations varied by ⁤age and sex, with atopic dermatitis correlating ⁢more strongly in those under 20, iron ⁤deficiency in those aged 50 to 69, acne vulgaris in men, and anxiety disorders in women.

Data limitations, including inconsistent sources and quality, likely led to an underestimation of alopecia areata burden in some underserved countries. Low diagnostic ‌rates and limited treatment access in these regions further impacted assessment.

“Future research should focus on unraveling the underlying mechanisms linking alopecia areata to its comorbid conditions,⁣ exploring regional disparities in disease burden, and identifying modifiable risk factors,” study authors concluded.

What’s next

Further studies are needed to understand the complex interplay of ⁢genetic, ‌environmental, and socioeconomic factors contributing ⁣to ⁢alopecia areata. Addressing data ⁢limitations and improving diagnostic rates in underserved regions are also crucial for a complete assessment of the global burden of this condition.